Therefore interfering with COL1 appears as a promising strategy in breast cancer, although the role of the other components of ECM e.g., proliferation increasing properties of fibronectin have to be kept in mind and are maybe more relevant for other cancer entities [38]. This evidence concerns the gene FN1 and breast cancer.